Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Total Liabilities (2016 - 2025)

CV Sciences' Total Liabilities history spans 14 years, with the latest figure at $5.5 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 12.0% year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, down 12.0%, while the annual FY2024 figure was $6.1 million, 2.62% down from the prior year.
  • Total Liabilities for Q3 2025 was $5.5 million at CV Sciences, down from $6.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $18.7 million in Q1 2021 and bottomed at $5.5 million in Q3 2025.
  • The 5-year median for Total Liabilities is $6.4 million (2024), against an average of $9.8 million.
  • The largest annual shift saw Total Liabilities rose 10.81% in 2022 before it crashed 56.84% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $14.5 million in 2021, then fell by 6.95% to $13.5 million in 2022, then tumbled by 53.4% to $6.3 million in 2023, then decreased by 2.62% to $6.1 million in 2024, then decreased by 11.02% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for CVSI's Total Liabilities are $5.5 million (Q3 2025), $6.1 million (Q2 2025), and $5.9 million (Q1 2025).